Calling for rapid development of a safe and effective MERS vaccine

Microbes and Infection

Volumn 16, Issue 7, 2014, Pages 529-531

  Hotez, Peter J ^a   Bottazzi, Maria Elena ^a   Tseng, Chien Te K ^b   Zhan, Bin ^a   Lustigman, Sara ^c   Du, Lanying ^c   Jiang, Shibo ^c,d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c NEW YORK BLOOD CENTER   (United States)

^d FUDAN UNIVERSITY   (China)

Author keywords

Coronavirus; MERS CoV; Receptor; Receptor binding domain; Vaccine

Indexed keywords

MIDDLE EAST RESPIRATORY SYNDROME VACCINE; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VITRONECTIN; VIRUS PROTEIN;

CORONAVIRUS; CORONAVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; CORONAVIRUS INFECTIONS; HEALTH; IMMUNOLOGY; MOUSE; PANDEMICS;

CORONAVIRUS;

ANIMALS; CORONAVIRUS INFECTIONS; GLOBAL HEALTH; HUMANS; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMICS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 84903730455     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2014.05.002     Document Type: Editorial

References (14)

1. http://news.sciencemag.org/health/2013/07/mers-virus-not-yet-global-emergency-who-panel-says.
2. MERS-CoV summary updates. http://www.who.int/csr/don/2014_05_23_mers/en/.
3. http://www.emro.who.int/media/news/mers-cov-mission-saudi-arabia.html.
4. Bloom Harold The anxiety of influence: a theory of poetry 1997, Oxford University Press, USA.
5. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
6. Englund J. In Search of a vaccine for respiratory syncytial virus: the Saga continues. J Infect Dis 2005, 191:1036-1039.
7. Jaume M., Yip M.S., Cheung C.Y., Leung H.L., Li P.H., Kien F., et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway. J Virol 2011, 85:10582-10597.
8. Tseng C.T., Sbrana E., Iwata-Yoshikawa N., Newman P.C., Garron T., Atmar R.L., et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 2012, 7:e35421.
9. Du L., He Y., Zhou Y., Liu S., Zheng B.J., Jiang S. The spike protein of SARS-CoV: a target for vaccine and therapeutic development. Nat Rev Microbiol 2009, 7:226-236.
10. Jiang S., Bottazzi M.E., Du L., Lustigman S., Tseng C.T., Curti E., et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines 2012, 11:1405-1413.
11. Chen W.H., Du L., Chag S.M., Ma C., Tricoche N., Tao X., et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother 2013 Dec 19, 10(3). [Epub ahead of print].
12. Du L., Zhao G., Kou Z., Ma C., Sun S., Poon V.K., et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013, 87:9939-9942.
13. Du L., Kou Z., Ma C., Tao X., Wang L., Zhao G., et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS ONE 2013, 8:e81587.
14. Zhang N., Jiang S., Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines 2014 Apr 26, 761-774. [Epub ahead of print].